Comment on

• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  [No authors listed] [No authors listed] Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
• Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

  [No authors listed] [No authors listed] Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211. Pediatrics. 1998. PMID: 9794957